Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1966529 | 0.98 | HTR6 (0.41) | HTR6 | |
| SCHEMBL28175563 | 0.94 | HTR6 (0.36) | HTR6 | |
| SCHEMBL9557656 | 0.85 | HTR6 (0.36) | HTR6 | |
| Glycine SCHEMBL3848788 | 0.84 | SSTR4 (0.32) | HTR6SSTR4 | |
| SCHEMBL1386444 | 0.83 | MEN1 (0.33) | — | |
| SCHEMBL9557652 | 0.80 | — | — | |
| SCHEMBL21422730 | 0.80 | — | — | |
| SCHEMBL1956709 | 0.79 | — | — | |
| SCHEMBL28881685 | 0.79 | HTR6 (0.40) | HTR6 | |
| SCHEMBL30983675 | 0.72 | SMN1; SMN2 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115260234-A | 2-amino-4-amino aryl phospho-oxypyrimidine compound and preparation method and application thereof | 江苏医药职业学院 | 2022-11-01 | — | — | CN | claimed |
| CN-110372703-A | Five-ring heterocycles miazines compound and application thereof | 罗欣生物科技（上海）有限公司 | 2019-10-25 | — | — | CN | claimed |
| CN-115260234-A | 2-amino-4-amino aryl phospho-oxypyrimidine compound and preparation method and application thereof | 江苏医药职业学院 | 2022-11-01 | — | — | CN | disclosed |
| CN-112142773-A | Tetrahydropyrroloxazone and piperidoxazone compounds and preparation method thereof | 复旦大学 | 2020-12-29 | — | — | CN | disclosed |
| CN-110372703-A | Five-ring heterocycles miazines compound and application thereof | 罗欣生物科技（上海）有限公司 | 2019-10-25 | — | — | CN | disclosed |
| CN-103864770-A | Pyrimidinamine and pyridinamine Hedgehog signal conduction inhibitors | JIANGSU SIMCERE PHARMACEUTICAL | 2014-06-18 | — | — | CN | disclosed |
| US-7576083-B2 | Morpholinyl piperidine glycine transporter inhibitors | MERCK & CO., INC. (US) | 2009-08-18 | — | — | US | disclosed |
| US-20070249606-A1 | Morpholinyl Piperidine Glycine Transporter Inhibitors | MERCK SHARP & DOHME CORP. | 2007-10-25 | — | — | US | disclosed |
| CN-1308326-C | Process for preparing indolinone derivatives | PHARMACIA & UPJOHN CO LLC (US) | 2007-04-04 | — | — | CN | disclosed |
| WO-2005107469-A3 | MORPHOLINYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK & CO INC (US) | 2006-06-29 | — | — | WO | disclosed |
| WO-2005107469-A3 | MORPHOLINYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK & CO INC (US) | 2006-06-29 | — | — | WO | disclosed |
| WO-2005107469-A2 | MORPHOLINYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK & CO., INC. (US) | 2005-11-17 | — | — | WO | disclosed |
| WO-2005107469-A2 | MORPHOLINYL PIPERIDINE GLYCINE TRANSPORTER INHIBITORS | MERCK & CO., INC. (US) | 2005-11-17 | — | — | WO | disclosed |
| CN-1671693-A | Process for preparing indolinone derivatives | PHARMACIA & UPJOHN CO LLC (US) | 2005-09-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249606-A1 | Morpholinyl Piperidine Glycine Transporter Inhibitors | SLC1A1, SLC1A2, SLC6A7 | HTR6 257/4885SSTR4 1988/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.